Published November 25, 2021
| Version v1
Publication
Lysophosphatidyl-choline 16:0 mediates persistent joint pain through Acid-Sensing Ion Channel 3: preclinical and clinical evidences
Creators
- Jacquot, Florian
- Khoury, Spiro
- Labrum, Bonnie
- Delanoe, Kevin
- Pidoux, Ludivine
- Barbier, Julie
- Delay, Lauriane
- Bayle, Agathe
- Aissouni, Youssef
- Barriere, David
- Kultima, Kim
- Freyhult, Eva
- Hugo, Anders
- Kosek, Eva
- Ahmed, Aisha
- Jurczak, Alexandra
- Lingueglia, Eric
- Svensson, Camilla
- Breuil, Veronique
- Ferreira, Thierry
- Marchand, Fabien
- Deval, Emmanuel
Description
Rheumatic diseases are often associated to debilitating chronic joint pain, which remains difficult to treat and requires new therapeutic strategies. Here, we describe increased content of lysophosphatidyl-choline (LPC) 16:0 in the knee synovial fluids of two independent cohorts of patients with painful joint diseases. If LPC16:0 levels correlated with pain in patients with osteoarthritis (OA), they do not appear to be the hallmark of a particular joint disease. We found that intra-articular injections of LPC16:0 in mouse produce chronic pain and anxiety-like behaviors in both males and females with no apparent inflammation, peripheral nerve sprouting and damage, nor bone alterations. LPC16:0-induced persistent pain state is dependent on peripheral Acid-Sensing Ion Channel 3 (ASIC3), ultimately leading to central sensitization. LPC16:0 and ASIC3 thus appear as key players of chronic joint pain with potential implications in OA and possibly across others rheumatic diseases.
Additional details
Identifiers
- URL
- https://hal.archives-ouvertes.fr/hal-03187657
- URN
- urn:oai:HAL:hal-03187657v1
Origin repository
- Origin repository
- UNICA